Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same
The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, viral infections, including coronavirus infections.
1. A composition comprising:
(a) a vector comprising:
(i) a plasmid that encodes at least one coronavirus antigen protein, and
(ii) the at least one coronavirus antigen protein encoded by the plasmid; and
(b) a vector comprising α-galactosvlceramide (α-GalCer); and
(c) at least one pharmaceutically acceptable carrier,
wherein at least one of vector (a) and vector (b) is an intact, bacterially-derived minicell or killed bacterial cell.
2. The composition of claim 1 , wherein:
(a) vector (a) is a first intact, bacterially derived minicell or killed bacterial cell, and vector (b) is a second intact, bacterially derived minicell or killed bacterial cell; or
(b) vector (a) and vector (b) are the same intact, bacterially derived minicell or killed bacterial cell, comprising the α-GaCer, the plasmid that encodes at least one coronavirus antigen protein, and the at least one coronavirus antigen protein encoded by the plasmid; or
(c) one of vector (a) and vector (b) is not an intact, bacterially derived minicell or killed bacterial cell and the other of vector (a) and vector (b) is an intact, bacterially derived minicell or killed bacterial cell.
3. The composition of claim 1 , wherein the coronavirus antigen comprises or characterizes a virus selected from the group consisting of an Alphacoronavirus; a Colacovirus such as Bat coronavirus CDPHE15; a Decacovirus such as Bat coronavirus HKU10 or Rhinolophus ferrumequinum alphacoronavirus HuB-2013; a Duvinacovirus such as Human coronavirus 229E; a Luchacovirus such as Lucheng Rn rat coronavirus; a Minacovirus such as a Ferret coronavirus or Mink coronavirus 1; a Minunacovirus such as Miniopterus bat coronavirus 1 or Miniopterus bat coronavirus HKU8; a Myotacovirus such as Myotis ricketti alphacoronavirus Sax-2011; a nyctacovirus such as Nyctalus velutinus alphacoronavirus SC-2013; a Pedacovirus such as Porcine epidemic diarrhea virus or Scotophilus bat coronavirus 512; a Rhinacovirus such as Rhinolophus bat coronavirus HKU2; a Setracovirus such as Human coronavirus NL63 or NL63-related bat coronavirus strain BtKYNL63-9b; a Tegacovirus such as Alphacoronavirus 1; a Betacoronavirus; a Embecovirus such as Betacoronavirus 1, Human coronavirus OC43, China Rattus coronavirus HKU24, Human coronavirus HKU1 or Murine coronavirus; a Hibecovirus such as Bat Hp-betacoronavirus Zhejiang2013; a Merbecovirus such as Hedgehog coronavirus 1, Middle East respiratory syndrome-related coronavirus (MERS-CoV), Pipistrellus bat coronavirus HKU5 or Tylonycteris bat coronavirus HKU4; a Nobecovirus such as Rousettus bat coronavirus GCCDC1 or Rousettus bat coronavirus HKU9, a Sarbecovirus such as a Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome coronavirus (SARS-CoV) or Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19); a Deltacoronavirus; an Andecovirus such as Wigeon coronavirus HKU20; a Buldecovirus such as Bulbul coronavirus HKU11, Porcine coronavirus HKU15, Munia coronavirus HKU13 or White-eye coronavirus HKU16; a Herdecovirus such as Night heron coronavirus HKU19; a Moordecovirus such as Common moorhen coronavirus HKU21; a Gammacoronavirus; a Cegacovirus such as Beluga whale coronavirus SW1; and an Igacovirus such as Avian coronavirus.
4. The composition of claim 1 , wherein the coronavirus antigen protein:
(a) is encoded by a polynucleotide comprising the sequence of SARS-CoV-2, or a polynucleotide having at least 80% sequence identity to the polynucleotide comprising the sequence of SARS-CoV-2; and/or
(b) comprises or is characteristic of human coronavirus 229E, human coronavirus OC43, SARS-CoV, HCoV NL63, HKU1, MERS-CoV, or SARS-CoV-2; and/or
(c) comprises or is characteristic of SARS-CoV-2.
5. The composition of claim 1 , wherein the coronavirus antigen is from a SARS-CoV-2 variant.
6. The composition of claim 5 , wherein the SARS-CoV-2 variant is selected from the group consisting of:
(a) UK SARS-CoV-2 variant (B.1.1.7/VOC-202012/01);
(b) B.1.1.7 with E484K variant;
(c) B.1.617.2 (Delta) variant;
(d) B.1.617 variant;
(e) B.1.617.1 (Kappa) variant;
(f) B.1.617.3 variant;
(g) South Africa B.1.351 (Beta) variant;
(h) P.1 (Gamma) variant;
(i) B.1.525 (Eta) variant;
(j) B.1.526 (Iota) variant;
(k) Lambda (lineage C.37) variant;
(1) Epsilon (lineage B.1.429) variant;
(m) Epsilon (lineage B.1.427) variant;
(n) Epsilon (lineage CAL.20C) variant;
(o) Zeta (lineage P.2) variant;
(p) Theta (lineage P.3) variant;
(q) R.1 variant;
(r) Lineage B.1.1.207 variant;
(s) Lineage B.1.620 variant;
(t) a SARS-CoV-2 variant comprising a L452R Spike Protein Substitution;
(u) a SARS-CoV-2 variant comprising a E484K Spike Protein Substitution;
(v) a SARS-CoV-2 variant comprising a K417N Spike Protein Substitution;
(w) a SARS-CoV-2 variant comprising a E484K Spike Protein Substitution;
(x) a SARS-CoV-2 variant comprising a N501Y Spike Protein Substitution;
(y) a SARS-CoV-2 variant comprising a K417T Spike Protein Substitution;
(z) a SARS-CoV-2 variant comprising a E484K Spike Protein Substitution;
(aa) a SARS-CoV-2 variant comprising a N501Y Spike Protein Substitution;
(bb) SARs-CoV-2 variants having one or more of the following missense mutations: N440, L452R, S477G/N, E484Q, E484K, N501Y, D614G, P681H, P681R, and A701V; and
(cc) any combination of the above variants, substitutions, and/or mutations.
7. The composition of claim 5 , wherein the vector (a) additionally comprises at least one coronavirus antigen from a SARS-CoV-2 strain.
8. The composition of claim 7 , wherein the SARS-CoV-2 strain is selected from the group consisting of the L strain, the S strain, the V strain, the G strain, the GR strain, and the GH strain.
9. The composition of claim 7 , wherein the coronavirus antigen protein is encoded by a polynucleotide comprising the sequence of SARS-CoV-2, or a polynucleotide having at least 80% sequence identity to the polynucleotide comprising the sequence of SARS-CoV-2.
10. The composition of claim 1 , wherein the plasmid:
(a) encodes at least one of spike (S) protein, nucieocapsid (N) protein, membrane (M) protein, and envelope (E) protein of SARS-CoV-2 or a SARS-CoV-2 variant; and/or
(b) encodes the spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and the envelope (E) protein; and/or
(c) encodes the spike (S) protein of SARS-CoV-2 or a SARS-CoV-2 variant; and/or
(d) the receptor binding domain (RBD) of a Spike protein of SARS-CoV-2 or a SARS-CoV-2 variant.
11. The composition of claim 1 , wherein the composition is formulated for oral administration, injection, nasal administration, pulmonary administration, or topical administration.
12. A vaccine composition comprising at least one intact, bacterially-derived minicell or killed bacterial cell, and comprised within the minicell or cell:
(a) a plasmid encoding a Spike protein from one or more of SARS-CoV-2 variant Alpha (B.1.1.7.UK), SARS-CoV-2 variant Beta (B.1.351. SA), SARS-CoV-2 variant Delta (B.1.617.2 India), and/or SARS-CoV-2 variant Gamma (P.1 Brazil); and
(b) α-galactosvlceramide (α-GalCer).
13. The vaccine composition of claim 12 , wherein:
(a) the plasmid and the α-GalCer are comprised within a single minicell; and/or
(b) the plasmid encodes the Spike protein from each of SARS-CoV-2 variant Alpha (B.1.1.7.UK), SARS-CoV-2 variant Beta (B.1.351. SA), SARS-CoV-2 variant Delta (B.1.617.2 India), and SARS-CoV-2 variant Gamma (P.1 Brazil).
14. A method of treating and/or vaccinating against a viral infection, comprising administering to a subject in need a composition according to claim 1 .
15. A method of treating and/or vaccinating against a viral infection, comprising administering to a subject in need a composition according to claim 5 .
16. A method of treating and/or vaccinating against a viral infection, comprising administering to a subject in need a composition according to claim 12 .
17. The method of claim 14 , wherein the subject:
(a) is suffering from or at risk of developing lymphopenia; and/or
(b) is deemed at risk for severe illness and/or serious complications from the viral infection; and/or
(c) is about age 50 or older, about age 55 or older, about age 60 or older, or about age 65 or older; and/or
(d) suffers from one or more pre-existing conditions selected from the group consisting of diabetes, asthma, a respiratory disorder, high blood pressure, and heart disease;
and/or
(e) is immunocompromised; and/or
(f) is immunocompromised due to AIDS, cancer, a cancer treatment, hepatitis, an auto-immune disease, steroid receiving, immunosenescence, or any combination thereof.
18. The method of claim 14 , wherein administration:
(a) increases the chance of survival following exposure to a coronavirus; and/or
(b) reduces the risk of transmission of coronavirus; and/or
(c) increases the chance of survival following exposure to a coronavirus by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, as measured using any clinically recognized technique; and/or
(d) reduces the risk of transmission of coronavirus by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, as measured using any clinically recognized technique.
19. The method of claim 14 , wherein administering is via any pharmaceutically acceptable method.
20. The method of claim 14 , wherein the subject:
(a) is exposed to or is anticipated to be exposed to an individual who is contagious for a coronavirus, and optionally wherein the individual who is contagious for a coronavirus has one or more symptoms selected from the group consisting of fever, cough, shortness of breath, diarrhea, sneezing, runny nose, and sore throat; and/or
(b) is a healthcare worker, aged 60 years or older, frequent traveler, military personnel, caregiver, or a subject with a preexisting condition that results in increased risk of mortality with infection.
21. The method of claim 14 , further comprising administering one or more antiviral drugs.
22. The method of claim 21 , wherein the one or more antiviral drugs are selected from the group consisting of chloroquine, darunavir, galidesivir, interferon beta, lopinavir, ritonavir, remdesivir, and triazavirin.
23. The method of claim 14 , wherein the α-GalCer induces a Th1 cytokine response in the subject, and optionally wherein the cytokine comprises IFNγ.
24. The method of claim 14 , wherein:
(a) a first minicell comprising the α-GalCer and a second minicell comprising the plasmid encoding at least one viral antigen are administered to the subject simultaneously; and/or
(b) a first minicell comprising the α-GalCer and a second minicell comprising the plasmid encoding at least one viral antigen are administered to the subject sequentially; and/or
(c) a first minicell comprising the α-GalCer and second minicells comprising the plasmid encoding at least one viral antigen are administered to the subject repeatedly; and/or
(d) a first minicell comprising the α-GalCer and second minicells comprising the plasmid encoding at least one viral antigen are administered to the subject at least once a week, twice a week, three times per week, or four times per week.
25. The composition of claim 2 , wherein vector (a) and vector (b) are the same intact, bacterially derived minicell or killed bacterial cell, comprising the α-GalCer, the plasmid that encodes at least one coronavirus antigen protein, and the at least one coronavirus antigen protein encoded by the plasmid, wherein at least some of the coronavirus antigen protein is present in the membrane of the intact bacterially derived minicell or killed bacterial cell.